Lipocine
LPCN
58 hedge funds and large institutions have $30.3M invested in Lipocine in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
23% more funds holding
Funds holding: 47 → 58 (+11)
2.65% more ownership
Funds ownership: 0% → 2.65% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $36.5M → $30.3M (-$6.18M)
Top Buyers
| 1 |
Millennium Management
New York
|
+$697K |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$684K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$270K |
| 4 |
Morgan Stanley
New York
|
+$192K |
| 5 |
RA
Royce & Associates
New York
|
+$179K |
Top Sellers
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.35M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$863K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$651K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$112K |
| 5 |
EEG
E.E. Geduld
|
-$55.9K |
LPCN Hedge Fund Activity: Q4 2016 in Review
58 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2016, worth a combined $30.3M — down 17% from $36.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LPCN positions and 3 closed out — a net gain of 11 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $697K. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $1.35M sold.
- 58 institutional investors held Lipocine (LPCN) as of Q4 2016, up from 47 in Q3 2016.
- Funds reported $30.3M of Lipocine stock for Q4 2016, down 17% quarter-over-quarter.
- 14 funds opened new Lipocine positions in Q4 2016 and 3 closed out, a net change of +11 holders.
- The largest Lipocine buyer in Q4 2016 was Millennium Management, an estimated $697K added.
- The largest Lipocine seller in Q4 2016 was Foresite Capital Management III, an estimated $1.35M sold.
Based on aggregated 13F filings for Q4 2016.